The company manufactures and sells medical devices, primarily absorbable and non-absorbable surgical sutures and threads used in cardiovascular and general surgeries for hospitals and nursing homes.
While the company claims a niche in cardiovascular sutures, the financials show a net margin of only 1.7% and an ROE of 3.3%, suggesting no durable competitive advantage. The lack of pricing power is evidenced by management's admission of extreme pricing pressure and a recent shift into a net loss despite revenue growth.
Earnings are primarily reinvested into inventory and backward integration for surgical threads, but these investments have failed to generate returns above the cost of capital, leading to a recent net loss and no dividends.
The company's inability to cover interest payments from operating profits eventually led to a liquidity crisis, as the 0.38 interest coverage ratio proved to be a terminal warning sign rather than a temporary dip. Capital tied up in stagnant inventory and unproductive backward integration projects failed to yield returns above the cost of capital, while the lack of pricing power in a commoditized market forced margins into a permanent negative spiral. The business eventually succumbed to its debt burden and regulatory scrutiny over non-compliant shareholding structures, leaving equity holders with a shell of a company that could no longer fund its own operations.
RichFakir rates Centenial Surgical Suture Ltd's business quality as poor — 28/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Centenial Surgical Suture Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Centenial Surgical Suture Ltd is: Not rated. A poor business at an expensive price — it does not make our shortlist right now. We marked it down a notch: revenue and earnings barely grow — a steady cash cow, not a compounder.
RichFakir's educational estimate of Centenial Surgical Suture Ltd's fair value is about ₹21 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →